Open AccessOutcomes with liquid biopsy to determine the EGFR mutation status in poor performance status, biopsy-ineligible, advanced NSCLC patients
Author(s) -
Avinash Pandey,
Sarjana Dutt,
Anjana Singh,
Amit Kumar,
Shivkant Singh
Publication year - 2019
Publication title -
cancer research statistics and treatment
Language(s) - English
Resource type - Journals
eISSN - 2590-3233
pISSN - 2590-3225
DOI - 10.4103/crst.crst_60_19
Subject(s) - medicine , t790m , liquid biopsy , biopsy , oncology , lung cancer , epidermal growth factor receptor , mutation , performance status , progression free survival , pathology , cancer , chemotherapy , gefitinib , gene , biology , biochemistry
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom